Anthropic IPOs on November 19 2026?
98% — undefined traders, $2573 volume
Articles across AI, biotech, forecasting, and emerging tech.
98% — undefined traders, $2573 volume
This article portrays an experiment on how good current frontier AIs are at producing detailed forecasting analyses. For this, I tasked Opus 5.5 to write an analysis on the effectiveness of AI safety advocacy work. Opus 5.5 decided to turn it into a broader forecast on the likelihood of a US-China AI deal by the end of 2030, and the cost effectiveness of various strategies for increasing that probability. At a later stage, it also added the likelihood of a US-China AI deal before complete automa...
31% — undefined traders, $37888 volume
1% — undefined traders, $33645 volume
36% — undefined traders, $3645 volume
46% — undefined traders, $7504 volume
95% — undefined traders, $6910 volume
97% — undefined traders, $140407 volume
21% — undefined traders, $6614 volume
1% — undefined traders, $4385 volume
76% — undefined traders, $3218 volume
2% — undefined traders, $2468 volume
6% — undefined traders, $23448 volume
98% — undefined traders, $76237 volume
73% — undefined traders, $4748 volume
1% — undefined traders, $10690 volume
3% — undefined traders, $6849 volume
76% — undefined traders, $28263 volume
44% — undefined traders, $5131 volume
Epistemic status: I’m confident in the question, unsure of the answer. This comes from working on healthcare AI in Nigeria, not from a dataset. I’d like to be proven wrong.A clinic, not far from herePicture a primary health clinic in northern Nigeria. One doctor, a few nurses, a queue that doesn’t end. Someone has installed an AI triage tool, and it’s good. It reads the symptoms, flags the urgent cases, and suggests a diagnosis in seconds. For a clinic that sees too many p...
.mjx-chtml {display: inline-block; line-height: 0; text-indent: 0; text-align: left; text-transform: none; font-style: normal; font-weight: normal; font-size: 100%; font-size-adjust: none; letter-spacing: normal; word-wrap: normal; word-spacing: normal; white-space: nowrap; float: none; direction: ltr; max-width: none; max-height: none; min-width: 0; min-height: 0; border: 0; margin: 0; padding: 1px 0} .MJXc-display {display: block; text-align: center; margin: 1em 0; padding: 0} .mjx-chtml[tabin...
1% — undefined traders, $14675 volume
19% — undefined traders, $50496 volume
44% — undefined traders, $352 volume
30% — undefined traders, $2953 volume
98% — undefined traders, $3164 volume
4% — undefined traders, $4333 volume
19% — undefined traders, $7881 volume
37% — undefined traders, $1174 volume
28% — undefined traders, $37969 volume
TL;DR: The movement has an evidence problem. To solve it, for each intervention we need to know:What types of evidence that intervention needsWhat types of evidence different sources can give usIn this post, we outline a framework for evidencing an intervention through five stages:Figure 1: The five stages of the evidence pipeline.Each stage poses a different question, needing different types of evidence, and thus different methods (and potentially different o...
10% — undefined traders, $5560 volume
[Subtitle.] I interviewed dozens of biosecurity experts. The fear that AI will enable lone wolves to build pandemics is a case study in how domain expertise gets sidelined.This is a crosspost for Why AI-assisted bioweapons won’t kill us all by Abi Olvera, which was published on Positive Sum on 20 July 2026. Here is a response from Olivia Scharfman, and here is Abi’s reply to it.Some of my friends think we are going to die because AI will make building a bioweapon easier.T...
7% — undefined traders, $6291 volume
62% — undefined traders, $11255 volume
26% — undefined traders, $3685 volume